Specific biochemical imbalance in the endorphin system, the stress center of the brain and gut, underlie the emotional and physical distress experienced by millions of sufferers of a wide variety of clinical conditions. The Endorphinergic Distress Syndrome is responsible, in part, for chronic anxiety, anger, depression, cravings, and pain hypersensitivity.
The endogenous opioid system has generally been associated with regulation of pain. Endogenous opioid system also modulates the experience of distress and play a central role in many psychiatric and neurodevelopmental disorders. Decades of preclinical research on the analgesic effects of endogenous opioids, like, endorphins, suggests that opioid receptors have inhibitory-excitatory properties.
An exploratory study using a cold pressor-induced pain paradigm, found evidence that a combination of a nutraceutical agent that enhances endorphin release with one that switches opioid receptors from an excitatory to inhibitory mode not only increased pain tolerance, but also reduced emotional and physical distress. This discovery led to clinical application of a critically formulated endorphinergic treatment in 203 case studies over a two-year period.
Findings revealed the remarkable clinical efficacy and safety of this treatment in the relief of chronic emotional and physical distress, including anxiety, anger, depression, cravings, and hyperalgesia, as well as enhancement of well-being, productivity, mental clarity, relationships, and an adaptive response to life’s stresses. The study provides new insights into the role of endogenous opioid system imbalances in the development, treatment, and prevention of dysfunctional emotional and physical distress.
It is postulated that an Endorphinergic Distress Syndrome consists of abnormal endorphin levels together with opioid receptors predominately in their excitatory mode. Endorphinergic Distress Syndrome account for many core distress symptoms associated with chronic anxiety, addictions, pain, as well as affective personality, autism spectrum, attention-deficit, and distress-related medical problems.
The research has led to new endorphinergic formulations, combining Endorphin Enhancers, such as caffeine, with Opioid Receptor Switchers, such as n-acetylcysteine, for the relief of emotional and physical distress. The study provides a novel method to reverse the anxiogenic effects of caffeine and related hyper-excitatory substances.